Business Overview: Aardvark Therapeutics, Inc. (NASDAQ: AARD)

---

Executive Summary

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic and endocrine diseases, with an initial focus on hyperphagia — the chronic, insatiable hunger that afflicts patients with rare genetic obesity disorders such as Prader-Willi Syndrome. The company's lead candidate, ARD-101, is an oral agonist of the GDF15-GFRAL appetite-signaling pathway, designed to suppress hunger through a peripheral (gut-restricted) mechanism rather than acting centrally on the brain like GLP-1 receptor agonists. Aardvark completed its Nasdaq IPO in 2024.

---

1. Core Business Model & How They Work

Aardvark is a pre-commercial biotech whose entire value proposition rests on advancing its pipeline through clinical trials toward FDA approval, initially in a rare-disease population before potentially expanding into broader metabolic indications.

[ GDF15-GFRAL Pathway Biology ] ➡ [ Oral Small-Molecule GFRAL Agonist (ARD-101) ]
     ➡ [ Orphan Disease Trials (Prader-Willi hyperphagia) ]
     ➡ [ Potential Broader Metabolic Disease Indications ]
     ➡ [ FDA Approval & Commercialization or Partnership ]

Key Operational Drivers

1. Novel, Differentiated Mechanism: Unlike systemic GLP-1 receptor agonists, ARD-101 is designed to act primarily on peripheral GFRAL receptors, aiming to suppress appetite while avoiding the nausea, vomiting, and muscle-loss side effects associated with centrally-acting weight-loss drugs.
2. Orphan Disease-First Strategy: By targeting Prader-Willi Syndrome hyperphagia — a severe, currently under-treated symptom with no fully satisfactory approved therapy — Aardvark can pursue a faster regulatory pathway (orphan drug designation, smaller trials) before expanding into broader obesity-adjacent markets.
3. Capital Deployment Discipline: As a single-indication-first clinical company, capital is concentrated on advancing ARD-101 through pivotal trials rather than diversifying across many early programs.

---

2. Pipeline

---

3. Competitive Landscape

                Central (Brain) Acting            Peripheral (Gut) Acting
                          │                                │
      Semaglutide/Tirzepatide ────────────────────  ARD-101 (Aardvark)
      (Novo Nordisk, Eli Lilly)                     (GFRAL agonist)
                          │                                │
      ────────────────────┼────────────────────────────────
                          │
              Prader-Willi-specific competitors
           (Soleno Therapeutics — Vykat XR/DCCR)

Competitors by Domain

Prader-Willi Syndrome / Rare Hyperphagia

• Key Competitors: Soleno Therapeutics (Vykat XR/diazoxide choline, FDA-approved for PWS hyperphagia), and earlier failed programs such as Levo Therapeutics' livoletide.
• Dynamics: With Soleno now having an approved competitor product, Aardvark must demonstrate meaningful differentiation in efficacy, tolerability, or a distinct mechanism to carve out share in this small but high-need population.

Broader Anti-Obesity / Metabolic Disease

• Key Competitors: Novo Nordisk (semaglutide/Wegovy) and Eli Lilly (tirzepatide/Zepbound), whose GLP-1-class drugs dominate the general obesity market.
• Dynamics: Aardvark is not trying to compete head-on with GLP-1s in mainstream obesity but is positioning ARD-101 as a differentiated, better-tolerated option, potentially even as a combination therapy alongside GLP-1s to counteract their gastrointestinal side effects.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Differentiated mechanism of action: A peripherally-restricted GFRAL agonist is mechanistically distinct from GLP-1 receptor agonists, potentially avoiding shared side-effect liabilities and opening combination-therapy opportunities.
• Orphan drug regulatory pathway: Targeting Prader-Willi hyperphagia allows for smaller, faster trials and potential orphan drug exclusivity if approved.
• Patent protection: Composition-of-matter and method-of-use patents around ARD-101 and the GFRAL mechanism provide a defensible IP position.

Strategic Risks & Vulnerabilities

1. Clinical trial risk: As with any clinical-stage biotech, ARD-101 could fail to show statistically significant benefit in pivotal trials.
   • Mitigation Strategy: Focus initial registration efforts on a well-characterized, high-unmet-need population (Prader-Willi hyperphagia) with clear, measurable endpoints (hyperphagia questionnaire scores).
2. Competitive approval by Soleno Therapeutics: A rival product already approved for the same indication raises the bar for differentiation and complicates trial recruitment and payer positioning.
   • Mitigation Strategy: Emphasize tolerability and mechanism differentiation, and explore combination or second-line positioning.
3. Single-asset, pre-revenue concentration: Nearly all corporate value depends on ARD-101's success; there is no diversified revenue base.
   • Mitigation Strategy: Pursue partnership or licensing discussions with larger pharma companies interested in the broader metabolic disease opportunity to de-risk and co-fund later-stage development.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Aardvark Therapeutics represents a focused bet on a differentiated appetite-suppression mechanism — peripheral GFRAL agonism — first validated in the high-unmet-need, orphan population of Prader-Willi Syndrome hyperphagia. Its scientific rationale offers a credible path to differentiate from both older Prader-Willi failures and the now-dominant GLP-1 class of obesity drugs.

The company's defining strategic question is whether ARD-101 can generate clean, differentiated clinical data — ideally showing meaningful hyperphagia improvement with a favorable tolerability profile — in a market where Soleno Therapeutics has already secured an approved competing product. A positive outcome could position Aardvark not only in Prader-Willi Syndrome but as a novel adjunct or alternative across the broader, rapidly growing metabolic disease and obesity treatment landscape.